Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00094848 · ClinicalTrials.gov registry record · Phase 2

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

A Phase 2 study, sponsored by Human Genome Sciences.

Completed
Registry status
Phase 2
Development phase

NCT00094848 is a Phase 2 study that has completed, run by Human Genome Sciences.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00094848, a Phase 2 study, has completed, sponsored by Human Genome Sciences.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

Interventions

  • DRUG TRAIL-R1 mAb (TRM-1; HGS-ETR1)

Trial Details

FieldValue
Start Date 2004-06
Est. Completion 2007-05
Phase Phase 2

Sponsor

Human Genome Sciences

17 total trials

What the Registry Record Tells You About NCT00094848

The ClinicalTrials.gov registry entry for NCT00094848 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which TRAIL-R1 mAb (TRM-1; HGS-ETR1) is the first listed.

NCT00094848 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00094848 about?

NCT00094848 is a clinical study titled "Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)". The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

What is the current status of trial NCT00094848?

This trial is currently completed. It is a Phase 2 study. The study started on 2004-06. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00094848?

The interventions under investigation include: TRAIL-R1 mAb (TRM-1; HGS-ETR1) (DRUG).

Who is sponsoring clinical trial NCT00094848?

This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.